Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NGFR | P08138 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HPD | P32754 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841558 | 0.85 | SLC16A1 (0.43) | SLC16A1ABCB11CYP3A4CYP2C9ADORA2B | |
| SCHEMBL3831679 | 0.83 | SLC16A1 (0.45) | SLC16A1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL3826819 | 0.81 | SLC16A1 (0.49) | SLC16A1ALDH1A1ABCB11CYP3A4CYP2C9 | |
| SCHEMBL3829619 | 0.79 | ADORA2B (0.45) | SLC16A1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL3826401 | 0.78 | ADORA2B (0.44) | SLC16A1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL4803812 | 0.75 | SLC16A1 (0.61) | SLC16A1ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL2208814 | 0.74 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTHPGDGAA | |
| SCHEMBL4840916 | 0.73 | SLC16A1 (0.51) | SLC16A1CYP3A4CYP2C9 | |
| SCHEMBL3833052 | 0.71 | SLC16A1 (0.43) | SLC16A1ALDH1A1KDM4ECYP3A4CYP2C9 | |
| SCHEMBL5097011 | 0.70 | SLC16A1 (0.47) | SLC16A1ABCB11CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080221131-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7393854-B2 | Thienopyrimidinedinones and their use in modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-07-01 | — | — | US | disclosed |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | ASTRAZENECA AB, A SWEDEN CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060135539-A1 | Thienopyridazinones and their use in modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221131-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE | TPMT, TYMP, TYMS | SLC16A1 4627/4885ALDH1A1 213/4885KDM4E 1729/4885 |
| US-20060135539-A1 | Thienopyridazinones and their use in modulation of autoimmune disease | TBXA2R, PTGER2, TBXAS1 | SLC16A1 4795/4885ALDH1A1 252/4885KDM4E 786/4885 |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | HRH4, HRH2, HRH3 | SLC16A1 4716/4885ALDH1A1 463/4885KDM4E 2323/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | SLC16A1 1397/4885ALDH1A1 401/4885KDM4E 181/4885 |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | SLC16A1 3284/4885ALDH1A1 84/4885KDM4E 1355/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885ALDH1A1 242/4885KDM4E 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.